V
Viktor Gruenwald
Researcher at Hannover Medical School
Publications - 37
Citations - 1270
Viktor Gruenwald is an academic researcher from Hannover Medical School. The author has contributed to research in topics: Renal cell carcinoma & Docetaxel. The author has an hindex of 11, co-authored 37 publications receiving 840 citations.
Papers
More filters
Journal ArticleDOI
Clinical activity and molecular correlates of response to atezolizumab alone or in combination with bevacizumab versus sunitinib in renal cell carcinoma
David F. McDermott,Mahrukh Huseni,Michael B. Atkins,Robert J. Motzer,Brian I. Rini,Bernard Escudier,Lawrence Fong,Richard W. Joseph,Sumanta K. Pal,James A. Reeves,Mario Sznol,John D. Hainsworth,W. Kimryn Rathmell,Walter M. Stadler,Thomas E. Hutson,Martin Gore,Alain Ravaud,Sergio Bracarda,Cristina Suarez,Riccardo Danielli,Viktor Gruenwald,Toni K. Choueiri,Dorothee Nickles,Suchit Jhunjhunwala,Elisabeth Piault-Louis,Alpa Thobhani,Jiaheng Qiu,Daniel S. Chen,Priti S. Hegde,Christina Schiff,Gregg Fine,Thomas Powles +31 more
TL;DR: Molecular profiles suggest that prediction of outcomes with anti-VEGF and immunotherapy may be possible and offer mechanistic insights into how blocking VEGF may overcome resistance to immune checkpoint blockade.
Journal ArticleDOI
Imatinib induces sustained progression arrest in RECIST progressive desmoid tumours: Final results of a phase II study of the German Interdisciplinary Sarcoma Group (GISG)
Bernd Kasper,Viktor Gruenwald,Peter Reichardt,Sebastian Bauer,Geraldine Rauch,Ronald Limprecht,Michaela Sommer,Antonia Dimitrakopoulou-Strauss,Lothar R. Pilz,Florian Haller,Peter Hohenberger +10 more
TL;DR: Imatinib induces sustained progression arrest in RECIST progressive desmoids tumour patients and nilotinib had the potential to stabilise desmoid tumour growth after treatment failure with imatinib.
Journal ArticleDOI
Circulating endothelial cells are an early predictor in renal cell carcinoma for tumor response to sunitinib.
Viktor Gruenwald,Gernot Beutel,Susanne Schuch-Jantsch,Christoph W. M. Reuter,Philipp Ivanyi,Arnold Ganser,Marion Haubitz +6 more
TL;DR: Sunitinib treatment is associated with an early increase of CEC in responding patients, suggesting superior endothelial cell damage in these patients as a putative predictive biomarker.
Journal ArticleDOI
Correlation of CTNNB1 Mutation Status with Progression Arrest Rate in RECIST Progressive Desmoid-Type Fibromatosis Treated with Imatinib: Translational Research Results from a Phase 2 Study of the German Interdisciplinary Sarcoma Group (GISG-01)
Bernd Kasper,Viktor Gruenwald,Peter Reichardt,Sebastian Bauer,Peter Hohenberger,Florian Haller +5 more
TL;DR: The positive correlation of CTNNB1 mutation status with the progression arrest rate after imatinib therapy supports the idea of a potential predictive impact of the mutation status on DF treatment decision making.
Journal ArticleDOI
Publisher Correction: Clinical activity and molecular correlates of response to atezolizumab alone or in combination with bevacizumab versus sunitinib in renal cell carcinoma.
David F. McDermott,Mahrukh Huseni,Michael B. Atkins,Robert J. Motzer,Brian I. Rini,Bernard Escudier,Lawrence Fong,Richard W. Joseph,Sumanta K. Pal,James A. Reeves,Mario Sznol,John D. Hainsworth,W. Kimryn Rathmell,Walter M. Stadler,Thomas E. Hutson,Martin Gore,Alain Ravaud,Sergio Bracarda,Cristina Suarez,Riccardo Danielli,Viktor Gruenwald,Toni K. Choueiri,Dorothee Nickles,Suchit Jhunjhunwala,Elisabeth Piault-Louis,Alpa Thobhani,Jiaheng Qiu,Daniel S. Chen,Priti S. Hegde,Christina Schiff,Gregg Fine,Thomas Powles +31 more
TL;DR: In the version of this article originally published, there was an error in Fig. 2n where the top line of the HR comparison chart originally was Atezo + bev vs sun.